MedPath

A comparison of the efficacy of botulinum toxin type A induced protective ptosis and temporary tarsorrhaphy in persistent corneal epithelial defect conditions. (Pilot study)

Phase 2
Recruiting
Conditions
Is the efficacy of botulinum toxin type A induced protective ptosis better than temporary tarsorrhaphy in persistent corneal epithelial defect?
persistent epithelial defect&#44
PED&#44
botulinum toxin&#44
tarsorrhaphy&#44
corneal epithelial defect
Registration Number
TCTR20130627002
Lead Sponsor
Ratchadapiseksompotch Research Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
11
Inclusion Criteria

This research is a pilot study. The sample size is 15 cases for each controlled and intervention group. The small number of sample size is due to limited PED cases. A total of 30 consecutive patients (1 affected eye for each patient) will be recruited from general eye clinic at the department of ophthalmology, King Chulalongkorn Memorial Hospital. This trial will be conducted between October 2012 to October 2014, The inclusion criteria is as followings:

Inclusion criteria :
1.Age > 18 year
2.Persistent corneal epithelial defect patient (1 affected eye for each patient)

Exclusion Criteria

Exclusion criteria :
1.Underlying disease that impairs corneal epithelial wound healing such as uncontrolled DM
2.Contraindications to Botulinum toxin type A (BOTOX) or temporary tarsorrhaphy
3.Uncontrolled corneal infection
4.Complications from PED : perforation , progressive thinning , active infection , not heal in 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
duration of complete healing (days) 3 months after end of the intervention duration of complete healing (days)
Secondary Outcome Measures
NameTimeMethod
size of healing area and cosmetic consideration 3 months after end of the intervention size of healing area and cosmetic consideration
© Copyright 2025. All Rights Reserved by MedPath